Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DFTX, ABVX, NERV, PMN, TRAX, and represent 54.33% of Ally Bridge Group's stock portfolio.
- Added to shares of these 10 stocks: DFTX (+$19M), ABVX (+$12M), TRAX (+$5.7M), AXSM, ASMB, CLYM, KURA, NERV, AVTX, PMN.
- Started 11 new stock positions in IBIO, TRAW, IDYA, KURA, CLYM, PALI, TRAX, AXSM, DFTX, ASMB. AVTX.
- Reduced shares in these 10 stocks: Soleno Therapeutics (-$13M), PRAX (-$11M), OVID (-$5.9M), CMPS (-$5.8M), TARS (-$5.7M), CMPX (-$5.3M), SLDB (-$5.1M), QURE, URGN, CAPR.
- Sold out of its positions in CAPR, CMPS, CMPX, IKT, KPTI, MAZE, PRAX, RLMD, REPL, Soleno Therapeutics. TARS, QURE.
- Ally Bridge Group was a net seller of stock by $-19M.
- Ally Bridge Group has $113M in assets under management (AUM), dropping by -8.68%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 25 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Definium Therapeutics Com Shs Call Option (DFTX) | 16.6 | $19M | NEW | 400k | 47.04 |
|
| Abivax Sa Sponsored Ads Call Option (ABVX) | 14.7 | $17M | +270% | 125k | 133.26 |
|
| Minerva Neurosciences Com New (NERV) | 10.7 | $12M | +31% | 2.2M | 5.55 |
|
| Promis Neurosciences Com Shs (PMN) | 7.2 | $8.2M | +49% | 620k | 13.16 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 5.1 | $5.7M | NEW | 284k | 20.12 |
|
| Axsome Therapeutics (AXSM) | 3.6 | $4.0M | NEW | 17k | 244.77 |
|
| Assembly Biosciences Com New (ASMB) | 3.4 | $3.8M | NEW | 140k | 27.48 |
|
| Aadi Bioscience (WHWK) | 3.3 | $3.7M | 818k | 4.58 |
|
|
| Edgewise Therapeutics (EWTX) | 3.0 | $3.4M | -48% | 83k | 40.63 |
|
| Eliem Therapeutics (CLYM) | 2.9 | $3.2M | NEW | 249k | 13.04 |
|
| Kura Oncology (KURA) | 2.8 | $3.2M | NEW | 290k | 10.97 |
|
| Cytomx Therapeutics (CTMX) | 2.6 | $2.9M | -13% | 775k | 3.75 |
|
| Avalo Therapeutics Sponsored Ads (AVTX) | 2.5 | $2.8M | NEW | 150k | 18.48 |
|
| Palisade Bio (PALI) | 2.3 | $2.6M | NEW | 1.2M | 2.09 |
|
| Solid Biosciences (SLDB) | 2.3 | $2.6M | -66% | 256k | 9.99 |
|
| An2 Therapeutics (ANTX) | 2.3 | $2.5M | 526k | 4.84 |
|
|
| Urogen Pharma (URGN) | 2.3 | $2.5M | -65% | 69k | 36.80 |
|
| Perspective Therapeutics Com New (CATX) | 2.2 | $2.5M | -19% | 744k | 3.41 |
|
| Ideaya Biosciences (IDYA) | 2.2 | $2.5M | NEW | 68k | 37.27 |
|
| Inventiva Sa Ads (IVA) | 2.1 | $2.4M | -14% | 635k | 3.78 |
|
| Alumis (ALMS) | 1.9 | $2.2M | -54% | 77k | 28.14 |
|
| Ovid Therapeutics (OVID) | 1.5 | $1.7M | -77% | 625k | 2.69 |
|
| Eupraxia Pharmaceuticals (EPRX) | 1.5 | $1.7M | -61% | 252k | 6.61 |
|
| Ibio Com New (IBIO) | 0.6 | $683k | NEW | 390k | 1.75 |
|
| Traws Pharma (TRAW) | 0.6 | $663k | NEW | 786k | 0.84 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2026 Q2 filed Aug. 14, 2026
- Ally Bridge Group 2026 Q1 filed May 18, 2026
- Ally Bridge Group 2025 Q4 filed Feb. 17, 2026
- Ally Bridge Group 2025 Q3 filed Nov. 14, 2025
- Ally Bridge Group 2025 Q2 filed Aug. 14, 2025
- Ally Bridge Group 2025 Q1 filed May 15, 2025
- Ally Bridge Group 2024 Q4 filed Feb. 14, 2025
- Ally Bridge Group 2024 Q3 filed Nov. 14, 2024
- Ally Bridge Group 2024 Q2 filed Aug. 14, 2024
- Ally Bridge Group 2024 Q1 filed May 15, 2024
- Ally Bridge Group 2023 Q4 filed Feb. 14, 2024
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022